Condition: Advanced Alveolar Soft Part Sarcoma · Advanced Soft Tissue Sarcoma · Metastatic Alveolar Soft Part Sarcoma · Sponsor: National Cancer Institute (NCI)
This phase II trial tests whether atezolizumab in combination with selinexor works to shrink tumors in patients with alveolar soft part sarcoma and whether the study drugs are better than the usual approach in treating this type of cancer. The usual approach is defined as care most people get for alveolar soft part sarcoma if they are not part of a clinical study, which includes treatment with radiation, kinase inhibitor drugs, immunotherapy drugs, or chemotherapy drugs. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may help keep cancer cells from growing and may kill them. Giving atezolizumab in combination with selinexor may help shrink tumors and stabilize the cancer in patients with alveolar soft part sarcoma.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Keck Medicine of USC Koreatown | Los Angeles, California, United States | Recruiting |
| Los Angeles General Medical Center | Los Angeles, California, United States | Recruiting |
| USC / Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Smilow Cancer Hospital Care Center at Saint Francis | Hartford, Connecticut, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care Center-Trumbull | Trumbull, Connecticut, United States | Recruiting |
| MedStar Georgetown University Hospital | Washington D.C., District of Columbia, United States | Suspended |
| National Cancer Institute Developmental Therapeutics Clinic | Bethesda, Maryland, United States | Recruiting |
| National Institutes of Health Clinical Center | Bethesda, Maryland, United States | Active Not Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
| University of Oklahoma Health Sciences Center | Oklahoma City, Oklahoma, United States | Recruiting |
| University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh, Pennsylvania, United States | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05333458